Patents Assigned to Steminent Biotherapeutics, Inc.
  • Patent number: 12042516
    Abstract: Provided are methods and articles of manufacture for use in stem cell therapy, for the treatment of diseases or conditions of SCA. Particularly, the invention provides a method for treating SCA, comprising parenterally or locally administering an effective amount of stem cells as a unit dosage to a subject, wherein the administration is performed with one or more treatment cycles, wherein one treatment cycle comprises dosing three unit dosages each at a dosing interval of two to six weeks.
    Type: Grant
    Filed: September 30, 2022
    Date of Patent: July 23, 2024
    Assignee: STEMINENT BIOTHERAPEUTICS INC.
    Inventors: Jennifer Hui-Chun Ho, Ryan Chang, Hsiu-Yu Lai, Wei-Kee Ong
  • Patent number: 11547730
    Abstract: Provided are methods and articles of manufacture for use in stem cell therapy, for the treatment of diseases or conditions of SCA. Particularly, the invention provides a method for treating SCA, comprising parenterally or locally administering an effective amount of stem cells as a unit dosage to a subject, wherein the administration is performed with one or more treatment cycles, wherein one treatment cycle comprises dosing three unit dosages each at a dosing interval of two to six weeks.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: January 10, 2023
    Assignee: STEMINENT BIOTHERAPEUTICS INC.
    Inventors: Jennifer Hui-Chun Ho, Ryan Chang, Hsiu-Yu Lai, Wei-Kee Ong
  • Publication number: 20150216908
    Abstract: The invention unexpectedly found that an isolated and modified QPSC population has multi-potentiality, including: osteoblasts (bone cells), chondrocytes (cartilage cells), and adipocytes (fat cells). The QPSC population of the invention features a desirable immunomodulation ability, including inducing, enhancing, or suppressing an immune response and thus has potential value in the prevention and/or treatment of various immune diseases/disorders/conditions. The invention has effective homing ability and regulation ability in complement-dependent cytotoxicity, including the ability to block the activation of host complements and direct migration to the target area and the ability to enhance cell viability, and thus offers better cell protection and therapeutic efficacy in vivo in the prevention and/or treatment of various acute tissue injury, ischemic or degenerative diseases/disorders/conditions.
    Type: Application
    Filed: February 6, 2015
    Publication date: August 6, 2015
    Applicant: STEMINENT BIOTHERAPEUTICS INC.
    Inventors: Oscar Kuang-Sheng Lee, Jennifer Hui-Chun Ho, Wei-Kee Ong, Yu-Hsuan Chu
  • Publication number: 20150024487
    Abstract: The present invention relates to a cryopreservative device comprising an outer case, one or more layers of space for the cryo-bags, and two or more Teflon cryopreservative bags. The outer case has a cover lip for opening and closing. The Teflon cryopreservative bags are filled with a freezing resistant. In the present invention, the cryo-bags and the Teflon cryopreservative bags are crossly stacked in the cryopreservation device. The Teflon cryopreservative bags are designed to directly contact with the cryo-bags in order to obtain the effect of slow cell freezing.
    Type: Application
    Filed: January 8, 2014
    Publication date: January 22, 2015
    Applicant: Steminent Biotherapeutics, Inc.
    Inventors: Cheng-Yi CHENG, Yu-Shan WU, Yin LIANG, Wei-Kee ONG, Hui-Chun HO